“E” to “Bath Salts”: Synthetic Psychostimulants and Hallucinogens Silas W. Smith, MD, FACEP CSAM. Addiction Medicine Review Course 2014. September 6, 2014 REFERENCES Presentation Bialer PA. Designer drugs in the general hospital. Psychiat Clin N Am. 2002;25:231-43. Babu KM, McCurdy CR, Boyer EW. Opioid receptors and legal highs: Salvia divinorum and Kratom. Clin Toxicol (Phila). 2008;46:146-52. Boyer EW, Babu KM, Adkins JE, McCurdy CR, Halpern JH. Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth). Addiction. 2008;103:1048-50. Braden MR, Parrish JC, Naylor JC, Nichols DE. Molecular interaction of serotonin 5- HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Mol Pharmacol. 2006;70:1956-64. Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One. 2011;6:e21917. Center for Substance Abuse Treatment, SAMHSA. Inhalants. Substance Abuse Treatment Advisory. March 2003;3(1):1-8. Chambers JJ, Kurrasch-Orbaugh DM, Parker MA, Nichols DE. Enantiospecific Synthesis and Pharmacological Evaluation of a Series of Super-Potent, Conformationally Restricted 5-HT2A/2C Receptor Agonists. J Med Chem. 2001;44:1003-10. Cohen BMZ, Butler R. BZP-party pills: A review of research on benzylpiperazine as a recreational drug. Int J Drug Policy. 2011;22:95-101. Compton DR, Johnson MR, Melvin LS, Martin BR. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther. 1992;260:201-209. Daly M, Simonson P. Street Drug Trends Survey 2011: The ketamine zone. Druglink. 2011;November/December:6-9. D'Souza DC, Ahn K, Bhakta S, Elander J, Singh N, Nadim H, Jatlow P, Suckow RF, Pittman B, Ranganathan M. Nicotine Fails to Attenuate Ketamine-Induced Cognitive Deficits and Negative and Positive Symptoms in Humans: Implications for Schizophrenia. Biol Psychiatry. 2012 Jun 18 [Epub ahead of print]. EMCDDA. GHB and its precursor GBL: an emerging trend case study. Thematic papers, European Monitoring Centre for Drugs and Drug Addiction. Lisbon; 2008. Available at: http://www.emcdda.europa.eu/publications/thematic-papers/ghb [accessed 14 Aug 2014]. Fantegrossi WE, Murnane KS, Reissig CJ. The behavioral pharmacology of hallucinogens. Biochem Pharmacol. 2008;75:17-33. Franklin PH, Murray TF. High affinity [3H]dextrorphan binding in rat brain is localized to a noncompetitive antagonist site of the activated N-methyl-D-aspartate receptor-cation channel. Mol Pharmacol. 1992;41:134-46. Gee P, Gilbert M, Richardson S, Moore G, Paterson S, Graham P. Toxicity from the recreational use of 1-benzylpiperazine. Clin Toxicol (Phila). 2008;46:802-7. Global Drug Survey. Facts and Figures. Published online at http://www.globaldrugsurvey.com/facts-figures/ [accessed 27 July 2014]. Gunderson EW, Haughey HM, Ait-Daoud N, Joshi AS, Hart CL. A survey of synthetic cannabinoid consumption by current cannabis users. Subst Abus. 2014;35:184-9. 1 “E” to “Bath Salts”: Synthetic Psychostimulants and Hallucinogens Silas W. Smith, MD, FACEP CSAM. Addiction Medicine Review Course 2014. September 6, 2014 Halpern JH, Sherwood AR, Hudson JI, Yurgelun-Todd D, Pope HG Jr. Psychological and cognitive effects of long-term peyote use among Native Americans. Biol Psychiatry. 2005;58:624-31. Hofmann A, Frey A, Ott H, Petrzilka T, Troxler F. Konstitutionsaufklärung und synthese von psilocybin. Experientia. 1958;14:107-109. Hsu CK, Chen YQ, Lung VZ, His SC, Lo HC, Shyu HY. Myelopathy and polyneuropathy caused by nitrous oxide toxicity: a case report. Am J Emerg Med. 2012;30:1016.e3-6. Jansen KLR. A review of the nonmedical use of ketamine: use, users and consequences. J Psychoactive Drugs. 2000;32:419-33. JHP Pharmaceuticals LLC. Prescribing Information. KETALAR - ketamine hydrochloride injection. Rochester, MI: JHP Pharmaceuticals, LLC, 2012. Johnston LD, O’Malley PM, Miech RA, Bachman JG, Schulenberg JE. Monitoring the Future. National results on drug use: 1975-2013: Overview, Key Findings on Adolescent Drug Use. Ann Arbor, MI: Institute for Social Research, The University of Michigan, 2014. Kapp FG, Maurer HH, Auwärter V, Winkelmann M, Hermanns-Clausen M. Intrahepatic Cholestasis Following Abuse of Powdered Kratom (Mitragyna speciosa). J Med Toxicol. 2011;7:227-31. Kendler KS, Jacobson KC, Prescott CA, Neale MC. Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. Am J Psychiatry. 2003;160:687-95. Lessenger JE, Feinberg SD. Abuse of prescription and over-the-counter medications. J Am Board Fam Med. 2008;21:45-54 Leung KS, Cottler LB. Ecstasy and other club drugs: a review of recent epidemiologic studies. Curr Opin Psychiatry. 2008;21:234-41. Licht CL, Christoffersen M, Okholm M, Damgaard L, Fink-Jensen A, Knudsen GM, Erritzoe D. Simultaneous polysubstance use among Danish 3,4- methylenedioxymethamphetamine and hallucinogen users: combination patterns and proposed biological bases. Hum Psychopharmacol. 2012;27:352-63. Lin JC, Bangs N, Lee HS, Kydd RR, Russell BR. Determining the subjective and physiological effects of BZP on human females. Psychopharmacology (Berl). 2009;207:439-46. Martín-Santos R, Torrens M, Poudevida S, Langohr K, Cuyás E, Pacifici R, Farré M, Pichini S, de la Torre R. 5-HTTLPR polymorphism, mood disorders and MDMA use in a 3-year follow-up study. Addict Biol. 2010;15:15-22. McWhirter L, Morris S. A case report of inpatient detoxification after kratom (Mitragyna speciosa) dependence. Eur Addict Res. 2010;16:229-31. Ng SH, Tse ML, Ng HW, Lau FL. Emergency department presentation of ketamine abusers in Hong Kong: a review of 233 cases. Hong Kong Med J. 2010;16:6-11. Nikolaou P, Papoutsis I, Stefanidou M, Spiliopoulou C, Athanaselis S. 2C-I-NBOMe, an "N-bomb" that kills with "Smiles". Toxicological and legislative aspects. Drug Chem Toxicol. 2014 May 1 (epub ahead of print). Parker MA, Marona-Lewicka D, Lucaites VL, Nelson DL, Nichols DE. A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor. J 2 “E” to “Bath Salts”: Synthetic Psychostimulants and Hallucinogens Silas W. Smith, MD, FACEP CSAM. Addiction Medicine Review Course 2014. September 6, 2014 Med Chem. 1998;41:5148-9. Parrott AC. MDMA and temperature: a review of the thermal effects of 'Ecstasy' in humans. Drug Alcohol Depend. 2012;121:1-9. Passie T, Seifert J, Schneider U, Emrich HM. The pharmacology of psilocybin. Addict Biol. 2002;7:357-64. Pendergraft WF 3rd, Herlitz LC, Thornley-Brown D, Rosner M, Niles JL. Nephrotoxic Effects of Common and Emerging Drugs of Abuse. Clin J Am Soc Nephrol. 2014 Jul 17. Persson J. Wherefore ketamine? Curr Opin Anaesthesiol. 2010;23:455-60. Prosser JM, Nelson LS. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol. 2012;8:33-42. Romanelli F, Smith KM. Dextromethorphan abuse: Clinical effects and management. Pharmacy Today. 2009;15:48-55. Sadzot B, Baraban JM, Glennon RA, Lyon RA, Leonhardt S, Jan CR, Titeler M. Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis. Psychopharmacology (Berl). 1989;98:495-9. Sanders-Bush E, Burris KD, Knoth K. Lysergic acid diethylamide and 2,5-dimethoxy-4- methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. J Pharmacol Exp Ther. 1988;246:924-8. Sarkar S, Schmued L. Neurotoxicity of ecstasy (MDMA): an overview. Curr Pharm Biotechnol. 2010;11:460-9. Schep LJ, Knudsen K, Slaughter RJ, Vale JA, Mégarbane B. The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol. Clin Toxicol (Phila). 2012;50:458-70. Sear JW. Ketamine hepato-toxicity in chronic pain management: another example of unexpected toxicity or a predicted result from previous clinical and pre-clinical data? Pain. 2011;152:1946-7. Steinkellner T, Freissmuth M, Sitte HH, Montgomery T. The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine. Biol Chem. 2011;392:103-15. Stone AL, Storr CL, Anthony JC. Evidence for a hallucinogen dependence syndrome developing soon after onset of hallucinogen use during adolescence. Int J Methods Psychiatr Res. 2006;153:116-30. Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-46, HHS Publication No. (SMA) 13-4795. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013. Substance Abuse and Mental Health Services Administration. The Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS): 2002-2012. National Admissions to Substance Abuse Treatment Services. BHSIS Series S-71, HHS Publication No. (SMA) 14-4850. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2014. 3 “E” to “Bath Salts”: Synthetic Psychostimulants and Hallucinogens Silas W. Smith, MD, FACEP CSAM. Addiction Medicine Review Course 2014. September 6, 2014 Tang MH,